RxDoctor Payments DataLook up a doctor →

Scott Cooper, MD

Neurology · Cumming, GANPI 1205843588

Payments from drug & device makers

$282,933in general payments, 2019–2025

Across 1,551 payments — averaging $182.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$127K
  • Teva Pharmaceuticals USA, Inc.$101K
  • UCB, Inc.$25K
  • Corium, LLC$8K
  • Avanir Pharmaceuticals, Inc.$5K
  • Biogen$2K
  • plus $15K from 54 others
$5,000in research payments, 2019–2025

Across 1 payment — averaging $5000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abbott$5K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)297$126,686
Teva Pharmaceuticals USA, Inc.199$100,740
UCB, Inc.167$25,309
Corium, LLC10$7,558
Avanir Pharmaceuticals, Inc.60$5,364
Biogen34$1,651
Novartis67$1,042
Pfizer71$998
SK Life Science, Inc.27$840
Lilly USA, LLC41$729
Neurocrine Biosciences, Inc.30$713
AstraZeneca(2 entities)29$706
Sunovion Pharmaceuticals Inc.37$672
Eisai Inc.29$659
Lundbeck LLC29$655
Amgen24$622
Amneal Pharmaceuticals LLC38$606
Otsuka America Pharmaceutical, Inc.25$558
MDD US Operations, LLC22$468
Sanofi24$454
Argenx US, Inc.19$449
Kyowa Kirin, Inc.22$402
Neurelis, Inc.18$398
Supernus Pharmaceuticals, Inc.20$350
Acorda Therapeutics, Inc15$318
Johnson & Johnson(2 entities)9$261
CSL Behring9$233
Biohaven Pharmaceutical Holding Company Ltd.12$216
Catalyst Pharmaceuticals, Inc.8$211
Acadia Pharmaceuticals Inc7$193
Sumitomo Pharma America, Inc.7$177
Jazz Pharmaceuticals Inc.7$162
Alnylam Pharmaceuticals Inc.6$151
Genentech USA, Inc.10$148
Adamas Pharmaceuticals, Inc.8$132
Zyla Life Sciences, Inc.14$129
ANI Pharmaceuticals, Inc.5$122
Bristol Myers Squibb6$118
Vanda Pharmaceuticals Inc.4$102
Grifols USA, LLC5$98
Takeda Pharmaceuticals U.S.A., Inc.4$97
Arbor Pharmaceuticals, Inc.6$96
Greenwich Biosciences, Inc.4$95
Biohaven Pharmaceuticals, Inc.4$95
Currax Pharmaceuticals LLC6$75
EMD Serono, Inc.3$63
Springworks Therapeutics, Inc.2$61
GE HealthCare2$57
Aprecia Pharmaceuticals, LLC3$56
Livanova USA, Inc.3$55
Daiichi Sankyo Inc.3$53
Merz Pharmaceuticals, LLC2$47
Aquestive Therapeutics, Inc.2$46
Mallinckrodt Enterprises LLC2$46
Portola Pharmaceuticals, LLC2$44
OWP Pharmaceuticals, Inc.3$44
Azurity Pharmaceuticals, Inc.2$42
Avion Pharmaceuticals2$39
Impel Pharmaceuticals Inc.3$38
Sanofi-aventis U.S. LLC2$37

How this compares

$282,933 in reported general payments places this provider in the 90th percentile of 506 neurology providers in Georgia.

See all neurology providers in Georgia →

Medicare billing

Part B allowed, 2024
$240,130
Medicare patients
609
Services billed
2,044

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Cumming

See the full list for Georgia →

Where these figures come from

Is this you, or does something look wrong? →